VORICONAZOLE-INDUCED HEPATOTOXICITY CONCISE UP-TO-DATE REVIEW
JOURNAL OF BASIC AND CLINICAL HEALTH SCIENCES, vol.6, no.1, pp.325-334, 2022 (ESCI, TRDizin)
- Publication Type: Article / Review
- Volume: 6 Issue: 1
- Publication Date: 2022
- Doi Number: 10.30621/jbachs.1051669
- Journal Name: JOURNAL OF BASIC AND CLINICAL HEALTH SCIENCES
- Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
- Page Numbers: pp.325-334
- Keywords: Voriconazole, Hepatotoxicity, Drug induced liver injury, plasma voriconazole concentration, CYP2C19 genotype
- Dokuz Eylül University Affiliated: Yes
Abstract
Voriconazole is a wide spectrum antifungal used primarily for invasive aspergillosis, an invasive mold infection occurs mostly in immunocompromised patients. Hepatotoxicity is the most common voriconazole-related adverse reaction that leads to treatment discontinuation. Even though reported incidence of hepatic adverse reactions during phase 2 and 3 clinical trials were less than 10%, observational studies in post marketing phase revealed much higher incidence reaching up to 69%. Therefore, the burden caused by hepatotoxicity and interruption of antifungal therapy put immunocompromised patients at serious risk.